Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best medical stocks to invest in according to billionaires. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) received a rating update from Bernstein on May 13. The firm lifted the price target on the stock to $46 from $35, maintaining a Market Perform rating on the shares and stating that biotech has had a solid start to 2026, up 11% year-to-date, outperforming Pharma and the S&P. The firm’s coverage is up 7% year-to-date on a simple-average basis, and down 3% cap weighted, and it overall maintains a positive view on the sector. Bernstein expects M&A and IPO activity to remain healthy, and considers the recent changes to FDA leadership as a tailwind, especially for less mature companies.

In its financial results for fiscal Q2 2026, ARWR provided insight into key REDEMPLO® commercial events, reporting that it continued to build consistent momentum since its independent launch in the United States. The total prescriptions received and in process to date exceeded 400, representing greater than 40% growth over just the last four weeks alone. The company also reported that a total of around 180 patients to date have received at least one pre-filled syringe shipment, and new weekly prescriptions are accelerating as well.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.